Serving Overlooked PatientsSM
Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity’s global footprint is over 50 countries, with a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Our medicines have benefited millions of people.
PRODUCT ANNOUNCEMENT
NOW AVAILABLE
Click for Full Prescribing Information,
including Indication, BOXED WARNING, and Important Safety Information.
PRODUCT ANNOUNCEMENT
Click for Full Prescribing Information, including Indication and Additional Safety Information.
PRODUCT ANNOUNCEMENT
NOW AVAILABLE
Click for Full Prescribing Information, including Indication, BOXED WARNING, and Important Safety Information.
PRODUCT ANNOUNCEMENT
Click for Full Prescribing Information, including Indication and Additional Safety Information.
OUR PRODUCTS
Azurity offers an ever expanding portfolio of products targeting key therapeutic areas.
News & Events
Azurity Pharmaceuticals Announces FerabrightTM (ferumoxytol injection) Now Available in the U.S. for Magnetic Resonance Imaging of the Brain
Woburn, MA — February 26, 2026 — Azurity Pharmaceuticals, Inc. announced today that FerabrightTM (ferumoxytol injection) is now available in the U.S. Ferabright is the first and only iron-based contrast agent indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier.1 Ferabright was approved by the U.S. Food and Drug Administration (FDA) in October 2025.
Azurity Pharmaceuticals Announces ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution, CII
Woburn, MA—February 10, 2026—Azurity Pharmaceuticals, Inc. announced that ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution will be available mid-2026 for treating ADHD in adults and pediatric patients 6 years and older. Arynta, a ready-to-use lisdexamfetamine oral solution that may be stored at room temperature between 68°F to 77°F (20°C to 25°C),1 received FDA approval in June 2025.